Entheon Biomedical Corp. (CSE:ENBI)

Entheon Biomedical Income Statement

Financials in millions CAD. Fiscal year is December - November.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	May 31, 2025	Nov 30, 2024	Nov 30, 2023	Nov 30, 2022	Nov 30, 2021	Nov 30, 2020
Revenue	-	-	0.25	0.19	-	-
Revenue Growth (YoY)	-	-	31.97%	-	-	-
Gross Profit	-	-	0.25	0.19	-	-
Selling, General & Admin	0.37	0.33	0.56	2.5	4.45	1.2
Research & Development	-	-	-	1.2	1.21	0.44
Operating Expenses	0.37	0.33	0.56	3.79	8.21	1.64
Operating Income	-0.37	-0.33	-0.31	-3.6	-8.21	-1.64
Interest & Investment Income	0.01	0.02	0.01	0	0.01	0.01
Currency Exchange Gain (Loss)	-0	-0	-0	0.02	0	-
Other Non Operating Income (Expenses)	-	-	0	0.25	-0	-2.74
EBT Excluding Unusual Items	-0.36	-0.32	-0.3	-3.33	-8.2	-4.38
Gain (Loss) on Sale of Investments	-	-	0	-0.07	0.21	0.05
Gain (Loss) on Sale of Assets	-	-	-	1.34	-	-
Other Unusual Items	-	-	-	-	-	-0.05
Pretax Income	-0.36	-0.32	-0.3	-2.06	-8	-4.38
Earnings From Continuing Operations	-0.36	-0.32	-0.3	-2.06	-8	-4.38
Earnings From Discontinued Operations	-	-	-	-6.46	-0.89	-
Net Income	-0.36	-0.32	-0.3	-8.52	-8.89	-4.38
Net Income to Common	-0.36	-0.32	-0.3	-8.52	-8.89	-4.38
Shares Outstanding (Basic)	11	8	6	6	5	3
Shares Outstanding (Diluted)	11	8	6	6	5	3
Shares Change (YoY)	74.11%	30.96%	-	8.85%	97.83%	543.78%
EPS (Basic)	-0.03	-0.04	-0.05	-1.44	-1.64	-1.60
EPS (Diluted)	-0.03	-0.04	-0.05	-1.44	-1.64	-1.60
Free Cash Flow	-0.39	-0.36	-0.36	-1.95	-5.33	-2.85
Free Cash Flow Per Share	-0.04	-0.05	-0.06	-0.33	-0.98	-1.04
Gross Margin	-	-	100.00%	100.00%	-	-
Operating Margin	-	-	-124.96%	-1898.18%	-	-
Profit Margin	-	-	-119.85%	-4492.23%	-	-
Free Cash Flow Margin	-	-	-143.79%	-1030.49%	-	-
EBITDA	-	-	-	-3.6	-8.18	-1.64
D&A For EBITDA	-	-	-	0	0.04	0
EBIT	-0.37	-0.33	-0.31	-3.6	-8.21	-1.64
EBIT Margin	-	-	-124.96%	-	-	-
Revenue as Reported	-	-	0.25	0.19	-	-

Updated Mar 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.